And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Our agenda is rather modest. Once again, we are taking in another installment in our “Let’s-see-them-before-they-die” concert series. We also plan to see the Pharmalot ancestors and, otherwise, catch up on some reading. And what about you? This is a fine time to enjoy the great outdoors. Perhaps, this is an opportunity to tidy up around the castle. Or reach out to someone special. Remember, life is short. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

Insys Therapeutics (INSY), whose former executive team was arrested for allegedly bribing doctors to prescribe its opioid painkiller, has set aside $150 million to cover a settlement amid ongoing talks with the U.S. Department of Justice, according to a filing with the Securities and Exchange Commission. This does not cover possible deals with various states or other organizations, but suggests a deal with DoJ “may be close at hand,” writes Jefferies analyst David Steinberg.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Given that the “EpiPen Jr” is so new a product, was this just completeness – “the agency received a total of 228 reports of EpiPen or EpiPen Jr. failures during the same time period” – or is the”Jr” significant nexus of failure? The referenced piece gives no clue – and the FDA may not have either but ‘it’s a thought.’

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy